Drugs / ISIS 416858
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03358030 | Dec 2017 → Jul 2019 | end stage renal failure | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02553889 | Oct 2015 → Nov 2016 | end stage renal failure | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01713361 | Oct 2012 → May 2014 | venous thromboembolism | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 416858 | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Known as | FXI-ASO | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Known as | IONIS-FXIRX | “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX, an Antisense...” NCT03358030 ↗ |
| Known as | ISIS-FXIRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01713361 ↗ |
| Action | Inhibit | “specifically reduces factor XI levels” PMID 25482425 ↗ Dec 2014 |
| Modality | Antisense oligonucleotide | “FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.” PMID 25482425 ↗ Dec 2014 |
| Route | Subcutaneous | “subcutaneously administered” NCT01713361 ↗ |
| Target | F11 | “specifically reduces factor XI levels” PMID 25482425 ↗ Dec 2014 |